Internal Reference Number: FOI_8356
Date Request Received: 03/01/2025 00:00:00
Date Request Replied To: 04/02/2025 00:00:00
This response was sent via: By Email
Request Summary: FOI Request on Biologics Rheumatology
Request Category: Researcher
| Question Number 1: Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: 路 Abatacept [Orencia] 路 Adalimumab [Humira] 路 Adalimumab Biosimilars 路 Apremilast [Otezla] 路 Baricitinib [Olumiant] 路 Bimekizumab [Bimzelx] 路 Certolizumab [Cimzia] 路 Etanercept [Enbrel] 路 Etanercept Biosimilars 路 Filgotinib [Jyseleca] 路 Golimumab [Simponi] 路 Guselkumab [Tremfya] 路 Infliximab [Remicade] 路 Infliximab Biosimilars 路 Ixekizumab [Taltz] 路 Risankizumab [Skyrizi] 路 Rituximab [MabThera] 路 Rituximab Biosimilars 路 Sarilumab [Kevzara] 路 Secukinumab [Cosentyx] 路 Tocilizumab [Ro Actemra] 路 Tocilizumab Biosimilars 路 Tofacitinib [Xeljanz] 路 Upadacitinib [Rinvoq] 路 Ustekinumab [Stelara] 路 Ustekinumab Biosimilar | |
| Answer To Question 1: Abatacept [Orencia] 47 路 Adalimumab [Humira] 22 路 Adalimumab Biosimilars 368 路 Apremilast [Otezla] 8 路 Baricitinib [Olumiant] 61 路 Bimekizumab [Bimzelx] 10 路 Certolizumab [Cimzia] 39 路 Etanercept [Enbrel] 11 路 Etanercept Biosimilars 157 路 Filgotinib [Jyseleca] 24 路 Golimumab [Simponi] 26 路 Guselkumab [Tremfya] 16 路 Infliximab [Remicade] 12 路 Infliximab Biosimilars 11 路 Ixekizumab [Taltz] 39 路 Risankizumab [Skyrizi] 0 路 Rituximab [MabThera] 14 路 Rituximab Biosimilars 14 路 Sarilumab [Kevzara] <5 路 Secukinumab [Cosentyx] 18 路 Tocilizumab [Ro Actemra] 27 路 Tocilizumab Biosimilars 41 路 Tofacitinib [Xeljanz] 19 路 Upadacitinib [Rinvoq] 66 路 Ustekinumab [Stelara] <5 路 Ustekinumab Biosimilar <5 | |
| Question Number 2: Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs: 路 Abatacept [Orencia] 路 Adalimumab [Humira] 路 Adalimumab Biosimilars 路 Apremilast [Otezla] 路 Bimekizumab [Bimzelx] 路 Certolizumab [Cimzia] 路 Etanercept [Enbrel] 路 Etanercept Biosimilars 路 Golimumab [Simponi] 路 Guselkumab [Tremfya] 路 Infliximab [Remicade] 路 Infliximab Biosimilars 路 Ixekizumab [Taltz] 路 Risankizumab [Skyrizi] 路 Secukinumab [Cosentyx] 路 Tofacitinib [Xeljanz] 路 Upadacitinib [Rinvoq] 路 Ustekinumab [Stelara] 路 Ustekinumab Biosimilar | |
| Answer To Question 2: Abatacept [Orencia] 0 路 Adalimumab [Humira] <5 路 Adalimumab Biosimilars 95 路 Apremilast [Otezla] 8 路 Bimekizumab [Bimzelx] 6 路 Certolizumab [Cimzia] 13 路 Etanercept [Enbrel] <5 路 Etanercept Biosimilars 28 路 Golimumab [Simponi] 8 路 Guselkumab [Tremfya] 16 路 Infliximab [Remicade] 0 路 Infliximab Biosimilars 0 路 Ixekizumab [Taltz] 37 路 Risankizumab [Skyrizi] 0 路 Secukinumab [Cosentyx] 5 路 Tofacitinib [Xeljanz] 15 路 Upadacitinib [Rinvoq] 9 路 Ustekinumab [Stelara] <5 路 Ustekinumab Biosimilar <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
